These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 21338259)

  • 21. Validation and application of an LC-MS/MS method for quantitation of three fatty acid ethanolamides as biomarkers for fatty acid hydrolase inhibition in human plasma.
    Jian W; Edom R; Weng N; Zannikos P; Zhang Z; Wang H
    J Chromatogr B Analyt Technol Biomed Life Sci; 2010 Jun; 878(20):1687-99. PubMed ID: 20462810
    [TBL] [Abstract][Full Text] [Related]  

  • 22. European Bioanalysis Forum recommendation: scientific validation of quantification by accelerator mass spectrometry.
    Higton D; Young G; Timmerman P; Abbott R; Knutsson M; Svensson LD
    Bioanalysis; 2012 Nov; 4(22):2669-79. PubMed ID: 23210650
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 'LC-electrolyte effects' improve the bioanalytical performance of liquid chromatography/tandem mass spectrometric assays in supporting pharmacokinetic study for drug discovery.
    Wang L; Sun Y; Du F; Niu W; Lu T; Kan J; Xu F; Yuan K; Qin T; Liu C; Li C
    Rapid Commun Mass Spectrom; 2007; 21(16):2573-84. PubMed ID: 17639570
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Applications of hyphenated LC-MS techniques in pharmaceutical analysis.
    Ermer J; Vogel M
    Biomed Chromatogr; 2000 Oct; 14(6):373-83. PubMed ID: 11002275
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The use of LC/MS, GC/MS, and LC/NMR hyphenated techniques to identify a drug degradation product in pharmaceutical development.
    Pan C; Liu F; Ji Q; Wang W; Drinkwater D; Vivilecchia R
    J Pharm Biomed Anal; 2006 Feb; 40(3):581-90. PubMed ID: 16242883
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Accelerator mass spectrometry allows for cellular quantification of doxorubicin at femtomolar concentrations.
    DeGregorio MW; Dingley KH; Wurz GT; Ubick E; Turteltaub KW
    Cancer Chemother Pharmacol; 2006 Feb; 57(3):335-42. PubMed ID: 16047147
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Biomedical accelerator mass spectrometry: recent applications in metabolism and pharmacokinetics.
    Lappin G; Stevens L
    Expert Opin Drug Metab Toxicol; 2008 Aug; 4(8):1021-33. PubMed ID: 18680438
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics of fexofenadine: evaluation of a microdose and assessment of absolute oral bioavailability.
    Lappin G; Shishikura Y; Jochemsen R; Weaver RJ; Gesson C; Houston B; Oosterhuis B; Bjerrum OJ; Rowland M; Garner C
    Eur J Pharm Sci; 2010 May; 40(2):125-31. PubMed ID: 20307657
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A monolithic-phase based on-line extraction approach for determination of pharmaceutical components in human plasma by HPLC-MS/MS and a comparison with liquid-liquid extraction.
    Naxing Xu R; Fan L; Kim GE; El-Shourbagy TA
    J Pharm Biomed Anal; 2006 Feb; 40(3):728-36. PubMed ID: 16289933
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Application of liquid chromatography-accelerator mass spectrometry (LC-AMS) to evaluate the metabolic profiles of a drug candidate in human urine and plasma.
    Prakash C; Shaffer CL; Tremaine LM; Liberman RG; Skipper PL; Flarakos J; Tannenbaum SR
    Drug Metab Lett; 2007 Aug; 1(3):226-31. PubMed ID: 19356047
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Simultaneous determination of four active alkaloids from a traditional Chinese medicine Corydalis saxicola Bunting. (Yanhuanglian) in plasma and urine samples by LC-MS-MS.
    Li HL; Zhang WD; Liu RH; Zhang C; Han T; Wang XW; Wang XL; Zhu JB; Chen CL
    J Chromatogr B Analyt Technol Biomed Life Sci; 2006 Feb; 831(1-2):140-6. PubMed ID: 16356790
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Applicability of bioanalysis of multiple analytes in drug discovery and development: review of select case studies including assay development considerations.
    Srinivas NR
    Biomed Chromatogr; 2006 May; 20(5):383-414. PubMed ID: 16307470
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Addressing metabolite safety during first-in-man studies using ¹⁴C-labeled drug and accelerator mass spectrometry.
    Lappin G; Seymour M
    Bioanalysis; 2010 Jul; 2(7):1315-24. PubMed ID: 21083242
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adding value through accelerator mass spectrometry-enabled first in human studies.
    Seymour MA
    J Labelled Comp Radiopharm; 2016 Dec; 59(14):640-647. PubMed ID: 27444819
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Regulatory considerations for development of bioanalytical assays for biotechnology products.
    Swann PG; Shapiro MA
    Bioanalysis; 2011 Mar; 3(6):597-603. PubMed ID: 21417729
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ternary-column system for high-throughput direct-injection bioanalysis by liquid chromatography/tandem mass spectrometry.
    Xia YQ; Whigan DB; Powell ML; Jemal M
    Rapid Commun Mass Spectrom; 2000; 14(2):105-11. PubMed ID: 10623938
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Determination of free and glucuronidated kaempferol in rat plasma by LC-MS/MS: application to pharmacokinetic study.
    Zhang WD; Wang XJ; Zhou SY; Gu Y; Wang R; Zhang TL; Gan HQ
    J Chromatogr B Analyt Technol Biomed Life Sci; 2010 Aug; 878(23):2137-40. PubMed ID: 20591752
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Applications of accelerator mass spectrometry for pharmacological and toxicological research.
    Brown K; Tompkins EM; White IN
    Mass Spectrom Rev; 2006; 25(1):127-45. PubMed ID: 16059873
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Microdose study of a P-glycoprotein substrate, fexofenadine, using a non-radioisotope-labelled drug and LC/MS/MS.
    Yamazaki A; Kumagai Y; Yamane N; Tozuka Z; Sugiyama Y; Fujita T; Yokota S; Maeda M
    J Clin Pharm Ther; 2010 Apr; 35(2):169-75. PubMed ID: 20456735
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Micro LC/MS in drug analysis and metabolism studies.
    Henion J; Skrabalak D; Dewey E; Maylin G
    Drug Metab Rev; 1983; 14(5):961-1003. PubMed ID: 6360611
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.